{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:16:36Z","timestamp":1791418596613,"version":"4.3.3"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:sec id=\"ab-coi240015-4\"><jats:title>Importance<\/jats:title><jats:p>Cisplatin is highly ototoxic but widely used. Evidence is lacking regarding cisplatin-related hearing loss (CRHL) in adult-onset cancer survivors with comprehensive audiologic assessments (eg, Words-in-Noise [WIN] tests, full-spectrum audiometry, and additional otologic measures), as well as the progression of CRHL considering comorbidities, modifiable factors associated with risk, and cumulative cisplatin dose.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240015-5\"><jats:title>Objective<\/jats:title><jats:p>To assess CRHL with comprehensive audiologic assessments, including the WIN, evaluate the longitudinal progression of CRHL, and identify factors associated with risk.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240015-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The Platinum Study is a longitudinal study of cisplatin-treated testicular cancer survivors (TCS) enrolled from 2012 to 2018 with follow-up ongoing. Longitudinal comprehensive audiologic assessments at Indiana University and Memorial Sloan Kettering Cancer Center included 100 participants without audiometrically defined profound hearing loss (HL) at baseline and at least 3.5 years from their first audiologic assessment. Data were analyzed from December 2013 to December 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240015-7\"><jats:title>Exposures<\/jats:title><jats:p>Factors associated with risk included cumulative cisplatin dose, hypertension, hypercholesterolemia, diabetes, tobacco use, physical inactivity, body mass index, family history of HL, cognitive dysfunction, psychosocial symptoms, and tinnitus.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240015-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Main outcomes were audiometrically measured HL defined as combined-ears high-frequency pure-tone average (4-12 kHz) and speech-recognition in noise performance measured with WIN. Multivariable analyses evaluated factors associated with risk for WIN scores and progression of audiometrically defined HL.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240015-9\"><jats:title>Results<\/jats:title><jats:p>Median (range) age of 100 participants at evaluation was 48 (25-67) years; median (range) time since chemotherapy: 14 (4-31) years. At follow-up, 78 (78%) TCS had audiometrically defined HL; those self-reporting HL had 2-fold worse hearing than TCS without self-reported HL (48 vs 24 dB HL; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). A total of 54 (54%) patients with self-reported HL showed clinically significant functional impairment on WIN testing. Poorer WIN performance was associated with hypercholesterolemia (\u03b2\u2009=\u20090.88; 95% CI, 0.08 to 1.69; <jats:italic>P<\/jats:italic>\u2009=\u2009.03), lower-education (<jats:italic>F<\/jats:italic><jats:sub>1<\/jats:sub>\u2009=\u20095.95; <jats:italic>P<\/jats:italic>\u2009=\u2009.004), and severity of audiometrically defined HL (\u03b2\u0302\u2009=\u20090.07; 95% CI, 0.06 to 0.09; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). CRHL progression was associated with hypercholesterolemia (\u03b2\u0302\u2009=\u2009\u22124.38; 95% CI, \u22127.42 to \u22121.34; <jats:italic>P<\/jats:italic>\u2009=\u2009.01) and increasing age (\u03b2\u0302\u2009=\u20090.33; 95% CI, 0.15 to 0.50; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Importantly, relative to age-matched male normative data, audiometrically defined CRHL progression significantly interacted with cumulative cisplatin dose (<jats:italic>F<\/jats:italic><jats:sub>1<\/jats:sub>\u2009=\u20095.98; <jats:italic>P<\/jats:italic>\u2009=\u2009.02); patients given 300 mg\/m<jats:sup>2<\/jats:sup> or less experienced significantly less progression, whereas greater temporal progression followed doses greater than 300 mg\/m<jats:sup>2<\/jats:sup>.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240015-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Follow-up of cisplatin-treated cancer survivors should include strict hypercholesterolemia control and regular audiological assessments. Risk stratification through validated instruments should include querying hearing concerns. CRHL progression relative to age-matched norms is likely associated with cumulative cisplatin dose; investigation over longer follow-up is warranted.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.1233","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:33:09Z","timestamp":1717687989000},"page":"912","source":"Crossref","is-referenced-by-count":25,"title":["Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy"],"prefix":"10.1001","volume":"10","author":[{"given":"Victoria A.","family":"Sanchez","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of South Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Paul C.","family":"Dinh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Indiana University, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick O.","family":"Monahan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science, Indiana University, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Althouse","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science, Indiana University, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennessa","family":"Rooker","sequence":"additional","affiliation":[{"name":"College of Nursing, University of South Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard D.","family":"Sesso","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eileen","family":"Dolan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Weinzerl","sequence":"additional","affiliation":[{"name":"Rehabilitation Services, Indiana University Health, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunkit","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Einhorn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Indiana University, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Frisina","sequence":"additional","affiliation":[{"name":"Department of Medical Engineering, University of South Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois B.","family":"Travis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Indiana University, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"23","key":"coi240015r1","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2016.66.8822","article-title":"Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer.","volume":"34","author":"Frisina","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi240015r2","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2006.07.9723","article-title":"Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.","volume":"25","author":"Knight","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi240015r3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2013.51.2038","article-title":"Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales\u2013a report from the Children\u2019s Oncology Group.","volume":"32","author":"Landier","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"coi240015r4","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-18-3179","article-title":"Clinical and genome-wide analysis of cisplatin-induced tinnitus implicates novel ototoxic mechanisms.","volume":"25","author":"El Charif","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"coi240015r5","first-page":"601","article-title":"Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide.","volume":"15","author":"Cianfrone","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"coi240015r6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/OP.22.00710","article-title":"Cisplatin-induced ototoxicity: a concise review of the burden, prevention, and interception strategies.","volume":"19","author":"Chattaraj","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"coi240015r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2022.102203","article-title":"Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis.","volume":"79","author":"Dillard","year":"2022","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"coi240015r8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.v61:2","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"coi240015r9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents.","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"coi240015r11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01456","article-title":"Patient-reported functional impairment due to hearing loss and tinnitus after cisplatin-based chemotherapy.","volume":"41","author":"Sanchez","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi240015r12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/0284186X.2021.1887514","article-title":"Speech perception 30 years after cisplatin-based chemotherapy in adults: limited clinical relevance of long-term ototoxicity?","volume":"60","author":"Skalleberg","year":"2021","journal-title":"Acta Oncol"},{"issue":"8","key":"coi240015r13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/0284186X.2018.1433323","article-title":"Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.","volume":"57","author":"Haugnes","year":"2018","journal-title":"Acta Oncol"},{"issue":"1","key":"coi240015r14","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1186\/s12885-021-08567-0","article-title":"Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.","volume":"21","author":"Paken","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"coi240015r15","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/hed.v41.2","article-title":"Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.","volume":"41","author":"Driessen","year":"2019","journal-title":"Head Neck"},{"issue":"1","key":"coi240015r16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142616","article-title":"Atorvastatin is associated with reduced cisplatin-induced hearing loss.","volume":"131","author":"Fernandez","year":"2021","journal-title":"J Clin Invest"},{"issue":"1","key":"coi240015r17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ygyno.2017.02.006","article-title":"Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.","volume":"145","author":"Skalleberg","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"coi240015r18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/AUD.0000000000000745","article-title":"Predicting speech-in-noise deficits from the audiogram.","volume":"41","author":"Shub","year":"2020","journal-title":"Ear Hear"},{"issue":"7","key":"coi240015r19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3766\/jaaa.22.7.3","article-title":"Clinical experience with the words-in-noise test on 3430 veterans: comparisons with pure-tone thresholds and word recognition in quiet.","volume":"22","author":"Wilson","year":"2011","journal-title":"J Am Acad Audiol"},{"issue":"2","key":"coi240015r20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/AUD.0000000000000486","article-title":"Characteristics of real-world signal to noise ratios and speech listening situations of older adults with mild to moderate hearing loss.","volume":"39","author":"Wu","year":"2018","journal-title":"Ear Hear"},{"issue":"1","key":"coi240015r21","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/s41467-017-01837-1","article-title":"Cisplatin is retained in the cochlea indefinitely following chemotherapy.","volume":"8","author":"Breglio","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"coi240015r22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5588\/ijtld.19.0062","article-title":"Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose.","volume":"24","author":"Hong","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"issue":"21","key":"coi240015r24","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1001\/jama.279.21.1715","article-title":"Cigarette smoking and hearing loss: the epidemiology of hearing loss study.","volume":"279","author":"Cruickshanks","year":"1998","journal-title":"JAMA"},{"issue":"9","key":"coi240015r25","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1002\/lary.v120:9","article-title":"A prospective study of cardiovascular risk factors and incident hearing loss in men.","volume":"120","author":"Shargorodsky","year":"2010","journal-title":"Laryngoscope"},{"key":"coi240015r26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.heares.2018.06.008","article-title":"Comorbidities of hearing loss and the implications of multimorbidity for audiological care.","volume":"369","author":"Besser","year":"2018","journal-title":"Hear Res"},{"issue":"4","key":"coi240015r27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/AUD.0b013e31817349d6","article-title":"The contribution of family history to hearing loss in an older population.","volume":"29","author":"McMahon","year":"2008","journal-title":"Ear Hear"},{"issue":"3","key":"coi240015r28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s10162-008-0123-1","article-title":"Occupational noise, smoking, and a high body mass index are risk factors for age-related hearing impairment and moderate alcohol consumption is protective: a European population-based multicenter study.","volume":"9","author":"Fransen","year":"2008","journal-title":"J Assoc Res Otolaryngol"},{"issue":"9","key":"coi240015r29","doi-asserted-by":"publisher","first-page":"E515","DOI":"10.1002\/lary.v130.9","article-title":"The relationship between cisplatin-related and age-related hearing loss during an extended follow-up.","volume":"130","author":"Skalleberg","year":"2020","journal-title":"Laryngoscope"},{"issue":"5","key":"coi240015r30","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.ijrobp.2008.07.034","article-title":"Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.","volume":"73","author":"Chan","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"coi240015r31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/0145561320949482","article-title":"Changes in vestibular function in patients with head-and-neck cancer undergoing chemoradiation.","volume":"101","author":"H\u00fclse","year":"2022","journal-title":"Ear Nose Throat J"},{"issue":"3S","key":"coi240015r32","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1044\/2021_AJA-21-00032","article-title":"A randomized controlled trial using automated technology for improving ototoxicity monitoring in VA oncology patients.","volume":"30","author":"Konrad-Martin","year":"2021","journal-title":"Am J Audiol"},{"issue":"8","key":"coi240015r33","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/bjc.1998.226","article-title":"Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.","volume":"77","author":"Bokemeyer","year":"1998","journal-title":"Br J Cancer"},{"issue":"5","key":"coi240015r34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/geront\/43.5.661","article-title":"The impact of hearing loss on quality of life in older adults.","volume":"43","author":"Dalton","year":"2003","journal-title":"Gerontologist"},{"issue":"3","key":"coi240015r35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/geront\/40.3.320","article-title":"Negative consequences of hearing impairment in old age: a longitudinal analysis.","volume":"40","author":"Strawbridge","year":"2000","journal-title":"Gerontologist"},{"issue":"6","key":"coi240015r36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0898264315614570","article-title":"Association of hearing loss and loneliness in older adults.","volume":"28","author":"Sung","year":"2015","journal-title":"J Aging Health"},{"issue":"5","key":"coi240015r37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1177\/0898264314529329","article-title":"Hearing loss in older persons: does the rate of decline affect psychosocial health?","volume":"26","author":"Pronk","year":"2014","journal-title":"J Aging Health"},{"issue":"2","key":"coi240015r38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/jamaoto.2017.2513","article-title":"Association of age-related hearing loss with cognitive function, cognitive impairment, and dementia: a systematic review and meta-analysis.","volume":"144","author":"Loughrey","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"10248","key":"coi240015r39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"issue":"15","key":"coi240015r40","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.2017.77.0735","article-title":"Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study.","volume":"36","author":"Kerns","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi240015r41","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1200\/JCO.2016.70.3108","article-title":"Multi-institutional assessment of adverse health outcomes among north american testicular cancer survivors after modern cisplatin-based chemotherapy.","volume":"35","author":"Fung","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"coi240015r42","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1002\/cam4.v11.14","article-title":"Pharmacogenomics of cisplatin-induced neurotoxicities: hearing loss, tinnitus, and peripheral sensory neuropathy.","volume":"11","author":"Zhang","year":"2022","journal-title":"Cancer Med"},{"issue":"3","key":"coi240015r43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/jnci\/djad236","article-title":"Impact of pain and adverse health outcomes on long-term U.S. testicular cancer survivors.","volume":"116","author":"Dinh","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"coi240015r44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamaoto.2014.42","article-title":"Hearing impairment associated with depression in US adults, National Health and Nutrition Examination Survey 2005-2010.","volume":"140","author":"Li","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"7","key":"coi240015r45","first-page":"493","article-title":"Uses and abuses of hearing loss classification.","volume":"23","author":"Clark","year":"1981","journal-title":"ASHA"},{"issue":"10","key":"coi240015r46","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3766\/jaaa.18.10.2","article-title":"Intra- and inter-session test, retest reliability of the Words-in-Noise (WIN) test.","volume":"18","author":"Wilson","year":"2007","journal-title":"J Am Acad Audiol"},{"issue":"6","key":"coi240015r47","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1682\/JRRD.2005.01.0009","article-title":"Use of 35 words for evaluation of hearing loss in signal-to-babble ratio: a clinic protocol.","volume":"42","author":"Wilson","year":"2005","journal-title":"J Rehabil Res Dev"},{"issue":"8","key":"coi240015r49","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"issue":"5","key":"coi240015r50","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11136-005-5370-6","article-title":"Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors.","volume":"15","author":"Oldenburg","year":"2006","journal-title":"Qual Life Res"},{"issue":"6","key":"coi240015r51","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/00003446-199012000-00004","article-title":"The hearing handicap inventory for adults: psychometric adequacy and audiometric correlates.","volume":"11","author":"Newman","year":"1990","journal-title":"Ear Hear"},{"issue":"5","key":"coi240015r52","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/00003446-199110000-00009","article-title":"Test-retest reliability of the hearing handicap inventory for adults.","volume":"12","author":"Newman","year":"1991","journal-title":"Ear Hear"},{"issue":"4","key":"coi240015r53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/14992020500057731","article-title":"Screened and unscreened hearing threshold levels for the adult population: results from the Nord-Tr\u00f8ndelag Hearing Loss Study.","volume":"44","author":"Engdahl","year":"2005","journal-title":"Int J Audiol"},{"issue":"5","key":"coi240015r54","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/0194599820910377","article-title":"Hearing loss, loneliness, and social isolation: a systematic review.","volume":"162","author":"Shukla","year":"2020","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"7","key":"coi240015r55","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/jamaoto.2020.0674","article-title":"Health-related quality of life changes associated with hearing loss.","volume":"146","author":"Dixon","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"10","key":"coi240015r56","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1093\/gerona\/glab144","article-title":"Association of hearing impairment with higher-level physical functioning and walking endurance: results from the Baltimore longitudinal study of aging.","volume":"76","author":"Martinez-Amezcua","year":"2021","journal-title":"J Gerontol: Series A"},{"issue":"10","key":"coi240015r57","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/14992027.2021.1976424","article-title":"The World Health Organization (WHO) hearing impairment guidelines and a speech recognition in noise (SRN) disorder.","volume":"61","author":"Vermiglio","year":"2022","journal-title":"Int J Audiol"},{"issue":"1","key":"coi240015r58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/14992027.2018.1518598","article-title":"The World Health Organization\u2019s hearing-impairment grading system: an evaluation for unaided communication in age-related hearing loss.","volume":"58","author":"Humes","year":"2019","journal-title":"Int J Audiol"},{"issue":"3","key":"coi240015r59","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/alz.v18.3","article-title":"Speech-in-noise hearing impairment is associated with an increased risk of incident dementia in 82,039 UK Biobank participants.","volume":"18","author":"Stevenson","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"8","key":"coi240015r60","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.ijporl.2010.05.011","article-title":"Cisplatinum ototoxicity in children, long-term follow up.","volume":"74","author":"Al-Khatib","year":"2010","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"10","key":"coi240015r61","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/01.mph.0000141348.62532.73","article-title":"Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.","volume":"26","author":"Bertolini","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"coi240015r62","doi-asserted-by":"publisher","first-page":"8929","DOI":"10.1038\/s41598-022-13023-5","article-title":"Predicting neural deficits in sensorineural hearing loss from word recognition scores.","volume":"12","author":"Grant","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"coi240015r63","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1002\/cam4.v12.3","article-title":"Comprehensive association analysis of speech recognition thresholds after cisplatin-based chemotherapy in survivors of adult-onset cancer.","volume":"12","author":"Shahbazi","year":"2023","journal-title":"Cancer Med"},{"issue":"2","key":"coi240015r64","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1121\/1.408469","article-title":"Development of the hearing in noise test for the measurement of speech reception thresholds in quiet and in noise.","volume":"95","author":"Nilsson","year":"1994","journal-title":"J Acoust Soc Am"},{"issue":"4","key":"coi240015r65","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1044\/1092-4388(2007\/059)","article-title":"An evaluation of the BKB-SIN, HINT, QuickSIN, and WIN materials on listeners with normal hearing and listeners with hearing loss.","volume":"50","author":"Wilson","year":"2007","journal-title":"J Speech Lang Hear Res"},{"issue":"4","key":"coi240015r66","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1121\/10.0014418","article-title":"Speech-in-noise testing: innovative applications for pediatric patients, underrepresented populations, fitness for duty, clinical trials, and remote services.","volume":"152","author":"Sanchez","year":"2022","journal-title":"J Acoust Soc Am"},{"key":"coi240015r67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1476-511X-12-95","article-title":"A clinical study of serum lipid disturbance in Chinese patients with sudden deafness.","volume":"12","author":"Weng","year":"2013","journal-title":"Lipids Health Dis"},{"issue":"3","key":"coi240015r68","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3233\/CH-131705","article-title":"Influence of blood lipids on plasma and blood viscosity.","volume":"57","author":"Irace","year":"2014","journal-title":"Clin Hemorheol Microcirc"},{"issue":"3","key":"coi240015r69","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1055\/s-0032-1315723","article-title":"Vascular pathophysiology in hearing disorders.","volume":"33","author":"Trune","year":"2012","journal-title":"Semin Hear"},{"key":"coi240015r70","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action.","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"coi240015r71","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2019.111079","article-title":"Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents.","volume":"136","author":"Santos","year":"2020","journal-title":"Food Chem Toxicol"},{"key":"coi240015r72","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejpb.2021.03.008","article-title":"Cisplatin-induced ototoxicity: updates on molecular mechanisms and otoprotective strategies.","volume":"163","author":"Tang","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"issue":"Pt B","key":"coi240015r73","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.heares.2015.02.009","article-title":"Synaptopathy in the noise-exposed and aging cochlea: primary neural degeneration in acquired sensorineural hearing loss.","volume":"330","author":"Kujawa","year":"2015","journal-title":"Hear Res"},{"key":"coi240015r74","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.695268","article-title":"Preferential cochleotoxicity of cisplatin.","volume":"15","author":"Prayuenyong","year":"2021","journal-title":"Front Neurosci"},{"issue":"8","key":"coi240015r75","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1097\/MAO.0000000000001069","article-title":"Speech-in-noise tests and supra-threshold auditory evoked potentials as metrics for noise damage and clinical trial outcome measures.","volume":"37","author":"Le Prell","year":"2016","journal-title":"Otol Neurotol"},{"key":"coi240015r23","author":"World Health Organization","year":"2021"},{"key":"coi240015r48","volume-title":"Statistical method in biological assay","author":"Finney","year":"1952"},{"key":"coi240015r10","unstructured":"SEER N. NCI SEER database, cancer stat facts: testicular cancer. Accessed April 25, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/testis.html"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2819649\/jamaoncology_sanchez_2024_oi_240015_1720732621.73765.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:04:04Z","timestamp":1721315044000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2819649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.1233","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}